Company* (Country; Symbol)

Company* (Country; Symbol)

Change from original agreement

Terms/Details (Date)

Corixa Corp. (CRXA) and GlaxoSmithKline plc (UK)

Biogen Idec Inc. (BIIB)

Companies settled all litigation related to patents on cancer radioimmunotherapy

Biogen is paying Corixa and GSK $20M up front, a milestone payment related to future Zevalin sales, and royalties on Zevalin sales until Bexxar patents expire in 2013 (3/1)

Crucell NV (the Netherlands; CRXL)

ML Laboratories plc (UK; LSE:MLB)

ML renewed its license to use Crucell's PER.C6 technology

The companies negotiated research and commercial terms covering gene therapy products; details were not disclosed (3/16)

Pharmacopeia Inc. (ACCL)

Celgene Corp. (CELG)

Extended and expanded deal under which Pharmacopeia will identify leads against selected Celgene targets

Pharmacopeia will receive research funding and could earn milestone and royalty payments (3/23)

SurroMed Inc.*

Biogen Idec Inc. (BIIB)

Extension to June 2002 deal to characterize responses to Biogen's Avonex in patients with multiple sclerosis

SurroMed is analyzing patient samples in its Biomarker Discovery Laboratory; terms were not disclosed (3/11)

Transgenomic Inc. (TBIO)

Geron Corp. (GERN)

Amended deal under which Transgenomic will provide additional compounds to Geron

The modified nucleic acid building block compounds will be used in the synthesis of Geron's cancer drug GRN163L; terms were not disclosed (4/28)


Immunomedics Inc. (IMMU)

Amgen Inc. (AMGN)

Amgen returned all rights to epratuzumab, a humanized CD22 monoclonal antibody licensed in December 2000

Amgen will get a five-year warrant to pur- chase 100,000 Immunomedics shares at $16 per share, and would get $600,000 if the drug is approved in the U.S.; those terms satsify all financial obligations (4/8)


* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

LSE = London Stock Exchange.